An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

University of Miami40 enrolled

Overview

This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Ranibizumab (PrONTO) study.

In this 2-year open-label, prospective, single-center, uncontrolled, investigator sponsored clinical study, neovascular AMD patients with subfoveal CNV (N=40) and a central retinal thickness of at least 300 µm as measured by optical coherence tomography (OCT) were enrolled to receive 3 consecutive monthly intravitreal injections of ranibizumab (0.5 mg). Thereafter, retreatment with ranibizumab was performed if one of the following changes were observed between visits: a loss of 5 letters in conjunction with fluid in the macula as detected by OCT, an increase in OCT central retinal thickness of at least 100 μm, new onset classic CNV, new macular hemorrhage, or persistent macular fluid following an injection of ranibizumab at the prior study visit.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Neovascular Age-related Macular Degeneration

Interventions

Ranibizumab (Lucentis)DRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 50 years or older * Active primary or recurrent macular neovascularization secondary to age-related macular degeneration (AMD) involving the central fovea in the study eye with evidence of disease progression * OCT central retinal thickness ≥ 300 microns * Best corrected visual acuity, using ETDRS charts, of 20/40 to 20/400 (Snellen equivalent) in the study eye Exclusion Criteria: * More than 3 prior treatments with verteporfin photodynamic therapy * Previous participation in a clinical trial (for either eye) involving antiangiogenic drugs (pegaptanib, ranibizumab, anecortave acetate, protein kinase C inhibitors) * Previous subfoveal focal laser photocoagulation in the study eye * Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding day 0 * Subfoveal fibrosis or atrophy in the study eye * History of vitrectomy surgery in the study eye * Aphakia or absence of the posterior capsule in the study eye * History of idiopathic or autoimmune-associated uveitis in either eye

Locations (1)

Bascom Palmer Eye Instiyute

Miami, Florida, United States

Outcomes

Primary Outcomes

Change in visual acuity vs baseline

Change in OCT central retinal thickness vs baseline

Secondary Outcomes

Number of injections over 1 year

Number of consecutive monthly injections until fluid-free

Injection free interval

Correlations of injection frequency with baseline lesion characteristics and visual acuity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.